Clinical Trials at Cancer Center and Research Institute - UMMC

Researchers at UMMC are committed to discovering new and innovative ways to prevent and treat the diseases that affect our daily lives, with the ultimate goal to improve the well-being of our families, friends, communities and future generations. However, we cannot do it alone. Clinical research studies are vital to the advancement of medicine and our vision to create "a healthier Mississippi."

Browse our ongoing clinical trials below, and use the left-hand filters to narrow your search.

To learn more about our clinical trials and how to participate, click here.


Search Filters Clear

Keywords
Study Categories
3 Total Trials for "Allergy/Asthma/Immunology"
2 Total Trials for "Arthritis/Rheumatology"
108 Total Trials for "Cancer"
20 Total Trials for "COVID-19 (Coronavirus)"
1 Total Trial for "Dermatology/Skin Care"
1 Total Trial for "Developmental Disorders"
12 Total Trials for "Digestive Conditions"
3 Total Trials for "Emergency Medicine"
2 Total Trials for "Endocrinology/Diabetes"
2 Total Trials for "Eyes/Vision"
6 Total Trials for "Genetics"
1 Total Trial for "Hearing"
20 Total Trials for "Heart Health"
8 Total Trials for "Infectious Diseases"
7 Total Trials for "Kidney/Renal Conditions"
1 Total Trial for "Liver Diseases"
20 Total Trials for "Lungs/Breathing"
2 Total Trials for "Men's Health"
8 Total Trials for "Neurosciences"
2 Total Trials for "Orthopaedics"
1 Total Trial for "Palliative Care"
47 Total Trials for "Pediatrics"
3 Total Trials for "Preventive Medicine"
2 Total Trials for "Rehabilitation Services"
1 Total Trial for "Sleep Medicine"
9 Total Trials for "Stroke/Traumatic Brain Injury"
10 Total Trials for "Surgery"
1 Total Trial for "Transplant"
1 Total Trial for "Weight Management"
16 Total Trials for "Women's Health"
Study Locations
Jackson Metro
Grenada
Holmes County
Study Status



Study Type

Biological Sex
Age
Study Phase




Other Criteria

Clinical Trials Displaying Items 1 - 20 of 89

March 25, 2024

A Phase 3, Randomized, Open Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R CHOP Compared to R CHOP in subjects with Newly Diagnosed Diffuse Large B Cell Lymphoma DLBCL EPCORE DLBCL2

Locations: Cancer Center and Research Institute - UMMC
November 20, 2023

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

Locations: Cancer Center and Research Institute - UMMC, University Hospital - UMMC
November 20, 2023

PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT*)

Locations: Cancer Center and Research Institute - UMMC, University Hospital - UMMC
November 20, 2023

A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2).

Locations: Cancer Center and Research Institute - UMMC, University Hospital - UMMC
November 20, 2023

INTEGRATION OF IMMUNOTHERAPY INTO ADJUVANT THERAPY FOR RESECTED NSCLC: ALCHEMIST CHEMO-IO (ACCIO)

Locations: Cancer Center and Research Institute - UMMC, University Hospital - UMMC
November 20, 2023

A RANDOMIZED PHASE III TRIAL COMPARING ACTIVE SYMPTOM MONITORING PLUS PATIENT EDUCATION VERSUS PATIENT EDUCATION ALONE TO IMPROVE PERSISTENCE WITH ENDOCRINE THERAPY IN YOUNG WOMEN WITH STAGE I-III BREAST CANCER (ASPEN)

Locations: Cancer Center and Research Institute - UMMC, University Hospital - UMMC
November 20, 2023

A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Locations: Cancer Center and Research Institute - UMMC, University Hospital - UMMC
November 20, 2023

A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy

Locations: Cancer Center and Research Institute - UMMC, University Hospital - UMMC
November 20, 2023

Tamibarotene in Combination with Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy

Locations: Cancer Center and Research Institute - UMMC, University Hospital - UMMC
November 20, 2023

Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage

Locations: Cancer Center and Research Institute - UMMC, University Hospital - UMMC
November 20, 2023

A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination with Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)

Locations: Cancer Center and Research Institute - UMMC, University Hospital - UMMC
November 20, 2023

Photobiomodulation Therapy Using the MuReva Phototherapy System to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Patients with Head and Neck Cancer Receiving Radiation Therapy with or without Concurrent Chemotherapy

Locations: Cancer Center and Research Institute - UMMC, University Hospital - UMMC
September 14, 2023

A Phase I, open-label, dose finding study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of OBT076, a CD205-directed antibody-drug conjugate, in recurrent and/or metastatic CD205-positive solid tumors and in women with CD205-positive HER2-negative metastatic breast cancer

Locations: Cancer Center and Research Institute - UMMC, University Hospital - UMMC
October 10, 2022

EF-32 A Pivotal Randomized, Open-Label Study of Optune® (TTFields, 200khz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Locations: Cancer Center and Research Institute - UMMC
July 19, 2022

S1900E: A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

Locations: Cancer Center and Research Institute - UMMC, University Hospital - UMMC
July 19, 2022

S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

Locations: Cancer Center and Research Institute - UMMC, University Hospital - UMMC
July 13, 2022

LAE205INT3101: A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients with Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies

Locations: Cancer Center and Research Institute - UMMC, University Hospital - UMMC
July 13, 2022

VX-20-121-102: A Phase 3 Study of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Locations: Cancer Center and Research Institute - UMMC
July 12, 2022

TO-TAS3681-101: A Phase 1, Open-Label, Non-Randomized, Safety, Tolerability, and Pharmacokinetic Study of TAS3681 in Patients with Metastatic Castration-Resistant Prostate Cancer

Locations: Cancer Center and Research Institute - UMMC, University Hospital - UMMC
July 12, 2022

S1937: A Phase III Randomized Trial of Eribulin with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

Locations: Cancer Center and Research Institute - UMMC, University Hospital - UMMC